Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2087-2093

  Ono, Katsuki ^a,b   Ueda, Hiroshi ^a,c   Yoshizawa, Yoshitaka ^a,c   Akazawa, Daisuke ^a,c   Tanimura, Ryuji ^a,c   Shimada, Ichio ^b,d   Takahashi, Hideo ^b  

^a Koto ku   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c Toray Branch Office of JBIC   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; GLYCOPROTEIN VI; LOSARTAN POTASSIUM; PHENYL GROUP; TETRAZOLE DERIVATIVE;

ARTICLE; COMPLEX FORMATION; COMPUTER MODEL; DRUG STRUCTURE; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; PROTEIN DOMAIN; SIMULATION; THROMBOCYTE AGGREGATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; KINETICS; LOSARTAN; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DYNAMICS SIMULATION; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 77949363102     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901534d     Document Type: Article

References (38)

1. Ruggeri, Z. M. Platelets in atherothrombosis. Nat. Med. 2002, 8, 1227-1234.
2. Nieswandt, B.; Watson, S. P. Platelet-collagen interaction: Is GPVI the central receptor? Blood 2003, 102, 449-461.
3. Farndale, R. W.; Sixma, J. J.; Barnes, M. J.; De Groot, P. G. The role of collagen in thrombosis and hemostasis. J. Thromb. Haemostasis 2004, 2, 561-573.
4. Nieswandt, B.; Brakebusch, C.; Bergmeier, W.; Schulte, V.; Bouvard, D.; Mokhtari-Nejad, R.; Lindhout, T.; Heemskerk, J. W.; Zirngibl, H.; Fassler, R. Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J. 2001, 20, 2120-2130.
5. Qian, M. D.; Villeval, J.-L.; Xiong, X.; Jandrot-Perrus, M.; Nagashima, K.; Tonra, J.; McDonald, K.; Goodearl, A.; Gill, D. Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library. Hum. Antibodies 2002, 11, 97-105.
6. Massberg, S.; Konrad, L; Bültmann, A.; Schulz, C.; Munch, G.; Peluso, M.; Lorenz, M.; Schneider, S.; Besta, F.; Muller, I.; Hu, B.; Langer, H.; Kremmer, E.; Rudelius, M.; Heinzmann, U.; Ungerer, M.; Gawaz, M. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004, 18, 397-399.
7. Krämer, C.; Sunkomat, J.; Witte, J.; Luchtefeld, M.; Waiden, M.; Schmidt, B.; Tsikas, D.; Böger, R. H.; Forssmann, W. G.; Drexler, H.; Schieffer, B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Ore. Res. 2002, 90, 770-779.
8. Schmidt, B.; Schieffer, B. Angiotensin II ATI receptor antagonists. Clinical implications of active metabolites. J. Med. Chem. 2003, 46, 2261-2270.
9. Kalinowski, L.; Matys, T.; Chabielska, E.; Buczko, W.; Malinski, T. Angiotensin II ATI receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002, 40, 521-527.
10. Wang, G. R.; Zhu, Y.; Halushka, P. V.; Lincoln, T. M.; Mendelsohn, M. E. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMPdependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4888-4893.
11. Montón, M.; Jiménez, A.; Núñez, A.; López-Blaya, A.; Farré, J.; Gómez, J.; Zalba, L. R.; Sánchez de Miduel, L.; Casado, S.; LópezFarré, A. Comparative effects of angiotensin II ATI-type receptor antagonists in vitro on human platelet activation. J. Cardiovasc. Pharmacol. 2000, 35, 906-913.
12. Grothusen, C.; Umbreen, S.; Konrád, I.; Stellos, K.; Schulz, C.; Schmidt, B.; Kremmer, E.; Teebken, O.; Massberg, S.; Luchtefeld, M.; Schieffer, B.; Gawaz, M. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of ATi-receptor antagonism. Arterioscler., Thromb., Vase. Biol. 2007, 27, 1184-1190.
13. Morton, L. F.; Hargreaves, P. G.; Farndale, R. W.; Young, R. D.; Barnes, M. J. Integrin α2β1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for α2β1independent platelet reactivity. Biochem. J. 1995, 306, 337-344.
14. Kehrel, B.; Wierwille, S.; Clemetson, K. J.; Anders, O.; Steiner, M.; Knight, C. G.; Farndale, R. W.; Okuma, M.; Barnes, M. J. Glycoprotein VI is a maj or collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 1998, 91, 491-499.
15. Knight, C. G.; Morton, L. F.; Onley, D. J.; Peachey, A. R.; Ichinohe, T.; Okuma, M.; Farndale, R. W.; Barnes, M. J. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc. Res. 1999, 41, 450-457.
16. Miura, Y.; Takahashi, T.; Jung, S. M.; Moroi, M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. J. Biol. Chem. 2002, 277, 46197-146104
17. 15N background for NMR studies of large proteins. J. Biomol. NMR 2007, 38, 89-98.
18. Horii, K.; Kahn, M. K.; Herr, A. B. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006, 108, 936-941.
19. Smethurst, P. A.; Joutsi-Korhonen, L.; O'Conner, M. N.; Wilson, E.; Jenning, N. S.; Gamer, S. F.; Zhang, Y.; Knight, C. G.; Dafforn, T. R.; Buckle, A.; IJsseldijk, M. J. W.; de Groot, P. G.; Watkins, N. A.; Farndale, R. W.; Ouwehand, W. H. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 2004, 105, 903-911.
20. O'Conner, M. N.; Smethurst, P. A.; Farndale, R. W.; Ouwehand, W. H. Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen. J. Thromb. Haemostasis 2006, 4, 869-873.
21. Kato-Takagaki, K.; Mizukoshi, Y.; Yoshizawa, Y.; Akazawa, D.; Torii, Y.; Ono, K.; Tanimura, Y.; Shimada, I.; Takahashi, H. Structural and interaction analysis of glycoprotein VI-binding peptide selected from phage display library. J. Biol. Chem. 2009, 284, 10720-10727.
22. Bertini, I.; Fragai, M.; Giachetti, A.; Luchinat, C.; Maletta, M.; Parigi, G.; Yen, K. J. Combining in silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases. J. Med. Chem. 2005, 48, 7544-7559.
23. Schieborr, U.; Vogtherr, H.; Eishorst, B.; Betz, M.; Grimme, S.; Pescatore, B.; Langer, T.; Saxena, K.; Schwalbe, H. How much NMR data is required to determine a protein-ligand complex structure? ChemBioChem 2005, 6, 1891-1898.
24. Constantine, K. L. Evaluation of site-directed spin labeling for characterizing protein-ligand complexes using simulated restraints. Biophys. J. 2001, 81, 1275-1284.
25. Stark, J.; Powers, R. Rapid protein-ligand costructures using chemical shift perturbations. J. Am. Chem. Soc. 2008, 130, 535-545.
26. Chabielska, E.; Pawlak, R.; Golatowski, J.; Rółkowski, R.; Pawlak, D.; Buczko, W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb. Res. 1998, 90, 271-278.
27. 1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am. J. Pathol. 2000, 157, 111-122.
28. Ezumi, Y.; Uchiyama, T.; Takayama, H. Molecular cloning, genomic structure, chromosomal localization, and alternative splice forms of the platelet collagen receptor glycoprotein VI. Biochem. Biophys. Res. Commun. 2000, 277, 27-36.
29. Pace, C. N.; Vajdos, F.; Lee, L.; Grimsley, G.; Gray, T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995, 4, 2411-2423.
30. Rich, R. L.; Kreikemeyer, B.; Owens, R. T.; LaBrenz, S.; Narayana, S. V. L.; Weinstock, G. M.; Murray, B. E.; Hook, M. Ace is a collagen-binding MSCRAMM from Enterococcusfaecalis. J. Biol. Chem. 1999, 274, 26939-26945.
31. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMR Pipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6, 277-293.
32. Keller, R.; Wüthrich, K. Computer-Aided Resonance Assignment (CARA). http://www.nmr.ch.
33. Fukunishi, Y.; Mikami, Y.; Nakamura, H. Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening. J. Mol. Graphics Modell. 2005, 24, 34-45.
34. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 2006, 49, 534-553.
35. Halgren, T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 2007, 69, 146-148.
36. Kim, J. G.; Fukunishi, Y.; Nakamura, H. Multicanonical molecular dynamics algorithm employing adaptive force-biased iteration scheme. Phys. Rev. E 2004, 057103.
37. Ryckaert, J. P.; Ciccotti, C.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular. J. Comput. Phys. 1977, 23, 327-341.
38. Goddard, T. D.; Kneller, D. G. SPARKY, version 3; University of California: San Francisco, CA, 2005.